Patents by Inventor Leonard Guarente
Leonard Guarente has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8652797Abstract: Methods of NAD-dependent of at least one lysine residue in an acetylated protein are disclosed. The methods include combining the acetylated protein with an isolated Sir2 protein or fragment that includes a core domain of the Sir2 protein. The Sir2 protein or fragment of the Sir2 protein can include a human Sir2 protein or a fragment of a human Sir2 protein.Type: GrantFiled: September 12, 2008Date of Patent: February 18, 2014Assignee: Massachusetts Institute of TechnologyInventors: Leonard Guarente, Shin-ichiro Imai, Christopher Armstrong
-
Patent number: 8642284Abstract: Methods of identifying agents which alter the NAD-dependent deacetylation activity of a Sir2 protein or a fragment of a Sir2 protein are disclosed. The acetylated protein can be a nuclear protein, such as a histone protein, or a cytoplasmic protein. The Sir2 protein employed in the methods can include at least a core domain of a Sir2 protein, such as a human Sir2 protein.Type: GrantFiled: December 13, 2000Date of Patent: February 4, 2014Assignee: Massachusetts Institute of TechnologyInventors: Leonard Guarente, Shin-Ichiro Imai, Christopher Armstrong
-
Publication number: 20130071378Abstract: Methods for screening a compound, by providing a test mixture comprising a transcription factor, Sir2, and a Sir2 cofactor with the compound, and evaluating an activity of a component of the test mixture in the presence of the compound are described.Type: ApplicationFiled: June 14, 2012Publication date: March 21, 2013Inventors: Leonard Guarente, Homayoun Vaziri, Shin-Ichiro Imai
-
Publication number: 20110009474Abstract: Provided herein are methods and compositions relating to sirtuin modulation of Wnt pathway signaling, including the use of sirtuin and sirtuin-modulating agents in the prevention and treatment of cancer and other diseases.Type: ApplicationFiled: April 14, 2008Publication date: January 13, 2011Applicants: President and Fellows of Harvard College, Massachusetts Institute of TechnologyInventors: David A. Sinclair, Ron Firestein, Leonard Guarente, Gil Blander
-
Publication number: 20100240029Abstract: A cholesterol-regulating complex of SIRT1 and LXR and methods of use are disclosed. SIRT1 forms a complex with LXR bound to an LXR element. Methods of forming the complex, identifying an agent that modulates formation of the complex, increasing the ratio of cholesterol bound to high density lipoprotein (HDL) to total cholesterol in the plasma of a mammal, promoting ABCA1-mediated cholesterol efflux from a mammalian cell, treating a subject deemed to have a level of SIRT1 activity that is below normal, assessing whether a candidate substance modulates an LXR-dependent process, and assessing whether a candidate substance modulates an SIRT1-dependent effect of an LXR are disclosed.Type: ApplicationFiled: June 6, 2007Publication date: September 23, 2010Applicant: Massachusetts Institute of TechnologyInventors: Leonard Guarente, Monty Krieger, Xiaoling Li
-
Publication number: 20100105036Abstract: This invention relates to methods of screening compounds that modulate cellular and organismal processes by modification of the activity of SIR2 and/or transcription factors, e.g., p53, particularly methods of screening for compounds that modify lifespan and/or metabolism of a cell or an organism by modulation of the activity of SIR2 and/or transcription factors, e.g., p53, and more particularly to methods of screening for compounds that modulate the activity of Sir2 and/or transcription factors, e.g., p53. In particular, the present invention relates to a method for screening a compound, by providing a test mixture comprising a transcription factor, Sir2, and a Sir2 cofactor with the compound, and evaluating an activity of a component of the test mixture in the presence of the compound. The invention further relates to therapeutic uses of said compounds.Type: ApplicationFiled: March 20, 2009Publication date: April 29, 2010Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Leonard Guarente, Homayoun Vaziri, Shin-Ichiro Imai
-
Patent number: 7572575Abstract: This invention relates to methods of screening compounds that modulate cellular and organismal processes by modification of the activity of SIR2 and/or transcription factors, e.g., p53, particularly methods of screening for compounds that modify lifespan and/or metabolism of a cell or an organism by modulation of the activity of SIR2 and/or transcription factors, e.g., p53, and more particularly to methods of screening for compounds that modulate the activity of Sir2 and/or transcription factors, e.g., p53. In particular, the present invention relates to a method for screening a compound, by providing a test mixture comprising a transcription factor, Sir2, and a Sir2 cofactor with the compound, and evaluating an activity of a component of the test mixture in the presence of the compound. The invention further relates to therapeutic uses of said compounds.Type: GrantFiled: April 13, 2006Date of Patent: August 11, 2009Assignees: Massachusetts Institute of Technology, Whitehead Institute for Biomedical ResearchInventors: Leonard Guarente, Homayoun Vaziri, Shin-Ichiro Imai
-
Publication number: 20090155834Abstract: Methods of identifying agents which alter the NAD-dependent acetylation status and mono-ADP-ribosylation of nuclear proteins are disclosed. The methods further include identifying agents which alter the life span or aging of a cell or an organism by determining the level of NAD-dependent acetylation and/or ADP ribosylation of a nuclear protein. The invention also relates to a mammalian Sir2 protein which acetylates or deacetylates nuclear proteins in a NAD-dependent manner and has mono-ADP-ribosyltransferase activity. Host cells producing the Sir2 protein and antibodies to the Sir2 protein are also provided.Type: ApplicationFiled: September 12, 2008Publication date: June 18, 2009Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: LEONARD GUARENTE, SHIN-ICHIRO IMAI, CHRISTOPHER ARMSTRONG
-
Patent number: 7452664Abstract: Methods of identifying agents which alter the NAD-dependent acetylation status and mono-ADP-ribosylation of nuclear proteins are disclosed. The methods further include identifying agents which alter the life span or aging of a cell or an organism by determining the level of NAD-dependent acetylation and/or ADP ribosylation of a nuclear protein. The invention also relates to a mammalian Sir2 protein which acetylates or deacetylates nuclear proteins in a NAD-dependent manner and has mono-ADP-ribosyltransferase activity. Host cells producing the Sir2 protein and antibodies to the Sir2 protein are also provided.Type: GrantFiled: December 15, 1999Date of Patent: November 18, 2008Assignee: Massachusetts Institute of TechnologyInventors: Leonard Guarente, Shin-ichiro Imai, Christopher Armstrong
-
Publication number: 20070099830Abstract: It has been discovered that Sirt4 possesses an ADP-ribosyltransferase activity. Sirt4 is localized to mitochondria, where it binds to and regulates the activity of proteins such as glutamate dehydrogenase. The ADP-ribosyltransferase activity of Sirt4 is important for the regulation of biological functions such as insulin secretion. Methods of screening for compounds that modulate the expression or activity of Sirt4 are provided. Also provided are methods of modulating insulin secretion, treating metabolic disorders, and treating neurodegenerative disorders by modulating the expression or activity of Sirt4.Type: ApplicationFiled: April 21, 2006Publication date: May 3, 2007Inventors: Leonard Guarente, Marcia Haigis
-
Publication number: 20060252076Abstract: This invention relates to methods of screening compounds that modulate cellular and organismal processes by modification of the activity of SIR2 and/or transcription factors, e.g., p53, particularly methods of screening for compounds that modify lifespan and/or metabolism of a cell or an organism by modulation of the activity of SIR2 and/or transcription factors, e.g., p53, and more particularly to methods of screening for compounds that modulate the activity of Sir2 and/or transcription factors, e.g., p53. In particular, the present invention relates to a method for screening a compound, by providing a test mixture comprising a transcription factor, Sir2, and a Sir2 cofactor with the compound, and evaluating an activity of a component of the test mixture in the presence of the compound. The invention further relates to therapeutic uses of said compounds.Type: ApplicationFiled: April 13, 2006Publication date: November 9, 2006Applicant: Massachusetts Institute of TechnologyInventors: Leonard Guarente, Homayoun Vaziri, Shin-Ichiro Imai
-
Publication number: 20050164969Abstract: The present invention provides new and advantageous methods, compositions, cell constructs and animal models related to inhibiting the senescence of vertebrate cells and vertebrate organisms based on the use of SIRT1 polynucleotides and polypeptides, as well as mutant SIRT1 polynucleotides and polypeptides. The invention provides polynucleotides that encode variants and fragments of SIRT1 polypeptides, and also provides variant SIRT1 polypeptides and fragments thereof. Additionally the invention provides a method of inhibiting or delaying the expression in a vertebrate cell of a protein having biological activity associated with loss of population doubling in the cell. The invention further provides a method of treating a pathology, a disease or a medical condition in a subject, wherein the pathology responds to an SIRT1 polypeptide.Type: ApplicationFiled: November 19, 2004Publication date: July 28, 2005Applicant: Massachusetts Institute of TechnologyInventors: Gil Blander, Leonard Guarente
-
Publication number: 20050136429Abstract: SIRT1 regulates the physiology of cells of the adipocyte lineage. Modulators of SIRT1 activity can be used to ameliorate, treat, or prevent diseases and disorders associated with adipose physiology, e.g., obesity, an obesity-related disease, or a fat-related metabolic disorder.Type: ApplicationFiled: July 6, 2004Publication date: June 23, 2005Inventors: Leonard Guarente, Frederic Picard
-
Publication number: 20050009169Abstract: Methods of isolating mutant yeast cells with increased life span, as well as mutant yeast cells isolated by the methods, are disclosed. Also described are methods of identifying agents which increase life span of yeast cells, and methods of isolating genes which affect senescence in organisms.Type: ApplicationFiled: August 5, 2004Publication date: January 13, 2005Inventors: Leonard Guarente, Nicanor Austriaco, James Claus, Francesca Cole, Brian Kennedy
-
Publication number: 20040005574Abstract: This invention relates to methods of screening compounds that modulate cellular and organismal processes by modification of the activity of SIR2 and/or transcription factors, e.g., p53, particularly methods of screening for compounds that modify lifespan and/or metabolism of a cell or an organism by modulation of the activity of SIR2 and/or transcription factors, e.g., p53, and more particularly to methods of screening for compounds that modulate the activity of Sir2 and/or transcription factors, e.g., p53. In particular, the present invention relates to a method for screening a compound, by providing a test mixture comprising a transcription factor, Sir2, and a Sir2 cofactor with the compound, and evaluating an activity of a component of the test mixture in the presence of the compound. The invention further relates to therapeutic uses of said compounds.Type: ApplicationFiled: July 8, 2002Publication date: January 8, 2004Inventors: Leonard Guarente, Homayoun Vaziri, Shin-Ichiro Imai